These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 31617856)

  • 1. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [No Abstract]   [Full Text] [Related]  

  • 8. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
    van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
    Tzaneva S; Geroldinger A; Trattner H; Tanew A
    Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis.
    Pan R; Wang X; Shu M; Das J; Kalra M; Wang Z
    Chin Med J (Engl); 2022 Jan; 135(1):11-19. PubMed ID: 34882622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for the treatment of adults with psoriasis.
    Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic analyses of psoriasis management: a systematic literature search.
    Gutknecht M; Krensel M; Augustin M
    Arch Dermatol Res; 2016 Nov; 308(9):601-616. PubMed ID: 27435415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
    Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
    Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.